ERRATUM Open Access



## Erratum to: 'Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs'

Jodel D. Pearson<sup>1</sup>, Jingxi Zhang<sup>1</sup>, Zuoqiao Wu<sup>1</sup>, Kayla D. Thew<sup>1</sup>, Katelynn J. Rowe<sup>1</sup>, Julinor T. C. Bacani<sup>2</sup> and Robert J. Ingham<sup>1\*</sup>

Unfortunately, the original version of this article [1] contained an error. A figure was mislabelled. In Figs. 5c and d the Doxorubicin (Doxo) concentrations should be in  $\mu M$ . Here is most recent version of the figure with it correctly labelled.

## **Author details**

<sup>1</sup>Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, University of Alberta, Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Canada. <sup>2</sup>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Received: 9 February 2016 Accepted: 9 February 2016 Published: 1 March 2016

## Reference

 Pearson JD, Zhang J, Wu Z, Thew KD, Rowe KJ, Bacani JTC, Ingham RJ. Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosisinducing drugs. Molecular Cancer. 2014;13:199.

## Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit






\* Correspondence: ringham@ualberta.ca

<sup>1</sup>Department of Medical Microbiology and Immunology and Li Ka Shing

and Health Research, University of Alberta, Edmonton, Canada

Institute of Virology, University of Alberta, Katz Group Centre for Pharmacy



**Fig. 5** From: Expression of granzyme B sensitizes ALK + ALCL tumour cells to apoptosis-inducing drugs. GzB knock-down reduces the sensitivity of ALK + ALCL cell lines to doxorubicin-induced apoptosis. SUP-M2 (a) or SR (b) cells expressing either control or GzB targeting shRNA were left untreated (untr.) or were treated with indicated concentrations of doxorubicin (Doxo) for 12 h at 37 °C. Cells were then lysed and lysates were probed with an anti-PARP antibody. The arrow indicates cleaved PARP. The anti-β-actin blot demonstrates equivalent protein loading. The percent cleaved PARP (% cleaved PARP) was determined by densitometry and represents the percentage of cleaved PARP as a fraction of total PARP. Molecular mass standards are indicated to the left of the western blots. SUP-M2 (c) or SR (d) cells expressing either control or GzB shRNA were left untreated (DMSO) or were treated with the indicated concentrations of doxorubicin (doxo) for 12 h at 37 °C. DNA fragmentation was then examined by TUNEL staining and results were expressed as the percentage of TUNEL-positive cells. The results shown represent the mean and standard deviation of 4 independent experiments. p values comparing cells expressing GzB shRNA to cells expressing control shRNA were obtained by performing paired, one-tailed t-tests. \*p < 0.05, \$p < 0.01, #p < 0.005, δp < 0.001